GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...

LYR-210 cut SNOT-22 scores by 22.4 points at week 24—over twice the minimal clinically important difference. Patients receiving LYR-210 needed fewer sinus surgeries than those in the sham group ...

SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that ...

MISSISSAUGA, ON, May 26, 2025 /CNW/ - GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance ...

GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and ...

SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials ...